PDCD1 and cancer: Initial evaluation of the anti-TIGIT mAb, OMP-31M32 (Etigilimab) in a phase Ia/b showed preclinical in vivo anti-tumor effects as a single agent and in combination with anti-PD-1 (NCT03119428) results presented at the Society for Immunotherapy of Cancer 2018).